FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2487303921> ?p ?o ?g. }

• W2487303921 endingPage "e0160221" @default.
• W2487303921 startingPage "e0160221" @default.
• W2487303921 abstract "Background Three checkpoint inhibitor drugs have been approved by the US Food and Drug Administration for use in specific types of cancers. While the results are promising, severe immunotherapy-related adverse events (irAEs) have been reported. Objectives To conduct a systematic review of case reports describing the occurrence of irAEs in patients with cancer following checkpoint blockade therapy, primarily to identify potentially unrecognized or unusual clinical findings and toxicity. Data Sources We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane CENTRAL with no restriction through August 2015. Study Selection Studies reporting cases of cancer develop irAEs following treatment with anti CTLA-4 (ipilimumab) or anti PD-1 (nivolumab or pembrolizumab) antibodies were included. Data Extraction We extracted data on patient characteristics, irAEs characteristics, how irAEs were managed, and their outcomes. Data Synthesis 191 publications met inclusion criteria, reporting on 251 cases. Most patients had metastatic melanoma (95.6%), and the majority were treated with ipilimumab (93.2%). Autoimmune colitis, hepatitis, endocrinopathies, and cutaneous irAEs were the most frequently reported irAEs in ipilimumab treated patients. A broad spectrum of toxicities were reported for almost every body system. Moreover, well-defined diseases such as sarcoidosis, polyarthritis, polymyalgia rheumatica/arteritis, lupus, celiac disease, dermatomyositis, and Vogt-Koyanagi-like syndrome were reported. The most frequent irAEs reported with anti-PD1 agents were dermatitis for pembrolizumab, and thyroid disease and pneumonitis for nivolumab. Complete resolution of adverse events occurred in most cases. However, persistent irAEs and death were reported, mainly in patients treated with ipilimumab. Limitations Our study is limited by information available in the original reports. Conclusions Evidence from case reports shows that cancer patients develop irAEs following checkpoint blockade therapy, and can occasionally develop clearly defined autoimmune systemic diseases. While discontinuation of therapy and/or treatment can result in resolution of irAEs, long-term sequelae and death have been reported." @default.
• W2487303921 created "2016-08-23" @default.
• W2487303921 creator A5000817838 @default.
• W2487303921 creator A5008096735 @default.
• W2487303921 creator A5065216794 @default.
• W2487303921 date "2016-07-29" @default.
• W2487303921 modified "2023-10-18" @default.
• W2487303921 title "Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports" @default.
• W2487303921 cites W1498940267 @default.
• W2487303921 cites W1914776013 @default.
• W2487303921 cites W1936956202 @default.
• W2487303921 cites W1971989824 @default.
• W2487303921 cites W1982086114 @default.
• W2487303921 cites W1982889687 @default.
• W2487303921 cites W1987030266 @default.
• W2487303921 cites W2002673340 @default.
• W2487303921 cites W2012104766 @default.
• W2487303921 cites W2013030792 @default.
• W2487303921 cites W2033009850 @default.
• W2487303921 cites W2066671159 @default.
• W2487303921 cites W2096322385 @default.
• W2487303921 cites W2097995306 @default.
• W2487303921 cites W2105057287 @default.
• W2487303921 cites W2107484016 @default.
• W2487303921 cites W2109653150 @default.
• W2487303921 cites W2116607009 @default.
• W2487303921 cites W2118982164 @default.
• W2487303921 cites W2130075738 @default.
• W2487303921 cites W2130085832 @default.
• W2487303921 cites W2133294507 @default.
• W2487303921 cites W2149827944 @default.
• W2487303921 cites W2157174922 @default.
• W2487303921 cites W2158728837 @default.
• W2487303921 cites W2160834915 @default.
• W2487303921 cites W2169351454 @default.
• W2487303921 cites W2265285917 @default.
• W2487303921 cites W2277230344 @default.
• W2487303921 cites W2341285800 @default.
• W2487303921 cites W865168492 @default.
• W2487303921 doi "https://doi.org/10.1371/journal.pone.0160221" @default.
• W2487303921 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4966895" @default.
• W2487303921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27472273" @default.
• W2487303921 hasPublicationYear "2016" @default.
• W2487303921 type Work @default.
• W2487303921 sameAs 2487303921 @default.
• W2487303921 citedByCount "349" @default.
• W2487303921 countsByYear W24873039212016 @default.
• W2487303921 countsByYear W24873039212017 @default.
• W2487303921 countsByYear W24873039212018 @default.
• W2487303921 countsByYear W24873039212019 @default.
• W2487303921 countsByYear W24873039212020 @default.
• W2487303921 countsByYear W24873039212021 @default.
• W2487303921 countsByYear W24873039212022 @default.
• W2487303921 countsByYear W24873039212023 @default.
• W2487303921 crossrefType "journal-article" @default.
• W2487303921 hasAuthorship W2487303921A5000817838 @default.
• W2487303921 hasAuthorship W2487303921A5008096735 @default.
• W2487303921 hasAuthorship W2487303921A5065216794 @default.
• W2487303921 hasBestOaLocation W24873039211 @default.
• W2487303921 hasConcept C121608353 @default.
• W2487303921 hasConcept C126322002 @default.
• W2487303921 hasConcept C143998085 @default.
• W2487303921 hasConcept C170493617 @default.
• W2487303921 hasConcept C197934379 @default.
• W2487303921 hasConcept C2778468042 @default.
• W2487303921 hasConcept C2780851360 @default.
• W2487303921 hasConcept C60644358 @default.
• W2487303921 hasConcept C71924100 @default.
• W2487303921 hasConcept C86803240 @default.
• W2487303921 hasConceptScore W2487303921C121608353 @default.
• W2487303921 hasConceptScore W2487303921C126322002 @default.
• W2487303921 hasConceptScore W2487303921C143998085 @default.
• W2487303921 hasConceptScore W2487303921C170493617 @default.
• W2487303921 hasConceptScore W2487303921C197934379 @default.
• W2487303921 hasConceptScore W2487303921C2778468042 @default.
• W2487303921 hasConceptScore W2487303921C2780851360 @default.
• W2487303921 hasConceptScore W2487303921C60644358 @default.
• W2487303921 hasConceptScore W2487303921C71924100 @default.
• W2487303921 hasConceptScore W2487303921C86803240 @default.
• W2487303921 hasFunder F4320337362 @default.
• W2487303921 hasIssue "7" @default.
• W2487303921 hasLocation W24873039211 @default.
• W2487303921 hasLocation W24873039212 @default.
• W2487303921 hasLocation W24873039213 @default.
• W2487303921 hasLocation W24873039214 @default.
• W2487303921 hasOpenAccess W2487303921 @default.
• W2487303921 hasPrimaryLocation W24873039211 @default.
• W2487303921 hasRelatedWork W2108026478 @default.
• W2487303921 hasRelatedWork W2292790189 @default.
• W2487303921 hasRelatedWork W2516455201 @default.
• W2487303921 hasRelatedWork W2779749872 @default.
• W2487303921 hasRelatedWork W2805103957 @default.
• W2487303921 hasRelatedWork W2891472322 @default.
• W2487303921 hasRelatedWork W3028011650 @default.
• W2487303921 hasRelatedWork W3185344136 @default.
• W2487303921 hasRelatedWork W3203117733 @default.
• W2487303921 hasRelatedWork W3214147810 @default.
• W2487303921 hasVolume "11" @default.

• next